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Abstract
Background: Split-thickness skin grafting (SSG) is an important modality for wound closure. However, the donor
site becomes a second, often painful wound, which may take more time to heal than the graft site itself and holds
the risk of infection and scarring. Epidermal grafting (EG) is an alternative method of autologous skin grafting that
harvests only the epidermal layer of the skin by applying continuous negative pressure on the normal skin to raise
blisters. This procedure has minimal donor site morbidity and is relatively pain-free, allowing autologous skin
grafting in an outpatient setting. We plan to compare EG to SSG and to further investigate the cellular mechanism
by which each technique achieves wound healing.
Methods/design: EPIGRAAFT is a multicentre, randomised, controlled trial that compares the efficacy and wound-
healing mechanism of EG with SSG for wound healing. The primary outcome measures are the proportion of
wounds healed in 6 weeks and the donor site healing time. The secondary outcome measures include the mean
time for complete wound healing, pain score, patient satisfaction, health care utilisation, cost analysis, and incidence of
adverse events.
Discussion: This study is expected to define the efficacy of EG and promote further understanding of the mechanism
of wound healing by EG compared to SSG. The results of this study can be used to inform the current best practise for
wound care.
Trial registration: Clinicaltrials.gov identifier, NCT02535481. Registered on 11 August 2015.
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Background
Split-thickness skin grafting (SSG) is a current standard
of care for wound closure for non-healing wounds. SSG
involves excision of the epidermis and part of the der-
mis, leaving behind the reticular dermis in the donor
site, which enables the skin to heal by secondary
intention [1]. Despite SSG being an important modality
for wound closure, the donor site becomes a second,
often painful wound, which may take more time to heal
than the graft site itself and holds the risk of infection
and scarring.
Epidermal grafting (EG) is an emerging and promising
option to overcome these challenges. Epidermal grafting
is a method of autologous skin grafting that harvests
only the epidermal layer of the skin from the donor site
by applying gentle heat and continuous negative pres-
sure on the normal skin to raise blisters [2, 3]. The roof
of the blister, which is the epidermis, is then excised and
transferred onto the wound. As the dermis in the donor
site remains untouched, the skin regenerates itself with-
out scarring. This procedure also causes minimum pain
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as the pain fibres in the dermis are unstimulated, allow-
ing autologous skin grafting in the outpatient setting
without the need for local anaesthesia.
This study evaluates the efficacy of EG using the
CelluTome Epidermal Harvesting System (Acelity, San
Antonio, TX, USA), an automated epidermal harvesting
system that produces an array of epidermal micro-grafts.
In a pilot study carried out in our centre using this
system, EG was noted to be an effective method of autolo-
gous skin grafting with complete wound healing achieved
in two-thirds of selected patients with minimal or no pain
and a scar-free donor site [3]. The ability to perform EG
in outpatient settings eliminates the need for a theatre
space and a hospital bed, with potentially better patient
satisfaction. However, it is not known if EG is an effective
clinical alternative to SSG.
The mechanism of wound healing by EG may be dif-
ferent compared to SSG. EG is postulated to promote
wound healing by expressing growth factors that acceler-
ate wound healing and encourage keratinocytes to mi-
grate from the wound edge [2]. We hypothesise that EG
has similar wound healing rates to SSG at 6 weeks but
with less donor site morbidity. We wish to evaluate the
efficacy of EG as an alternative to SSG and to further
investigate the mechanism by which each technique
achieves wound healing.
Methods/design
Trial design
This study is a multicentre, randomised, control trial
with two parallel groups. Eligible patients will be rando-
mised to EG or SSG using a computerized randomisa-
tion method. This protocol is reported in accordance to
the SPIRIT 2013 guideline (see Additional file 1) [4].
Research ethics approval
This trial has approval from the National Research
Ethics Service Committee London-Fulham (project ID:
15/LO/0556) and from the National Health Service Re-
search & Development Department, Royal Free Hospital
(project ID:9417). This trial is conducted in accordance
to the Declaration of Helsinki and the recommendations
of Good Clinical Practice.
Study setting
Participants will be recruited at the Royal Free Hospital
(RFH), London, and the University Hospital Wales, Cardiff.
The Royal Free Hospital is an academic teaching
hospital and is associated with the University College
London (UCL).
Eligibility criteria
Patients referred by consultant plastic surgeons for skin
grafting are eligible for the study. Before enrolment,
patients will be screened for inclusion in the trial, and a
patient information sheet will be given. This process will
include an explanation of the aims, methods of skin graft-
ing and subsequent wound management, anticipated ben-
efits, and potential hazards of the study. Patients are given
sufficient time (offered a period of 24 hours or more if
needed) to consider whether they wish to participate.
Patients will then be offered participation in the study, and
informed consent will be obtained (see Additional file 2).
Treatment will be given within 7 days of patient enrolment.
Inclusion criteria are as follows:
1. Age ≥ 18 years
2. Wound measuring more than 1 cm x 1 cm and less
than 6 cm x 6 cm (1 % total body surface area)
3. Clean, healthy granulating bed
4. Patients will be required to understand and be
willing to participate in the trial and be able to
comply with the weekly visits and follow-up regime
Exclusion criteria are as follows:
1. Infected wound
2. Wound at the plantar of the foot
3. Unsuitable for split-thickness skin grafting
4. Previous history of excessive bleeding associated
with surgical biopsies or trauma
5. Uncontrolled diabetes mellitus, as measured by
HbA1c ≥ 10 percent
6. Presence of one or more medical conditions
including renal, hepatic, hematologic, active
auto-immune or immune diseases
7. Use of systemic steroid or immunosuppressant
8. Not fit for surgery (ASA classification ≥ 4)
Interventions
Wound bed preparation
All wounds will be prepared per normal clinical practise,
which is either using the negative pressure wound therapy
(NPWT) or appropriate wound dressings to achieve a
healthy granulating bed. Wound swabs will be performed
to ensure no bacterial growth. During the time of wound
bed preparation, the patient will be referred to the re-
search team. When the wound bed is deemed ready for
grafting, as agreed on by two treating clinicians, patients
will then be screened and offered a patient information
sheet for inclusion in the trial. Once the patients are ready
for intervention, following review by the study team, pa-
tients will undergo informed consent and randomisation.
Epidermal graft
Prior to grafting, the wound will be cleaned using wound
irrigation solution by the surgeon and debrided if ne-
cessary. The suction head of the CelluTome Epidermal
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Harvesting System will be applied to the donor site (thigh)
for 30–40 minutes to harvest the epidermal graft per
protocol [3, 5]. The harvested epidermal grafts will then
be transferred onto the wound using a non-adhering sili-
cone dressing (Adaptic Touch, Systagenix, Airebank Mills,
Skipton, UK). The wound is then dressed with gauze or
NPWT, as deemed appropriate by the treating clinician
based on the type of the wound. The use of iNadine (Sys-
tagenix) will also be considered over the Adaptic Touch
for wounds that are more exudative or had previous infec-
tions. The dressing will be secured with a crepe bandage
or a Mepore dressing (Mölnlycke Health, Dunstable,
Bedfordshire, UK). The donor site will be dressed with
Tegaderm (3M). The wound and donor site will be
reviewed on day 7 ± 2 post-grafting.
Split-thickness skin graft
Patients will undergo this procedure in the operating
theatre under general or local anaesthesia. The wound
will be initially debrided by the treating surgeon in a
similar manner to the EG group. Skin will be harvested
from the thigh using an electric air dermatome, set to
cut at the thickness of 8–10/1000 inch, which will
then be meshed by 1:1.5. The wound will be grafted
and dressed with Adaptic Touch (Systagenix), gauze,
and a Mepore or wool and crepe bandage, depending
on the site of the graft. The donor site will be dressed
with Kaltostat (Alginate dressing) with a 2.5-cm overlay
beyond the wound margins and secured with Mefix.
Per standard clinical practise, the graft will be checked
at day 7 ± 2.
Wound exudate sampling and punch biopsy
Wound exudate sampling will be performed by applying
a filter paper (Whatman™ qualitative filter paper) on the
wound for 15 minutes until it is moist. The filter paper
will then be stored in a sterile vial and transferred to the
laboratory. The wound fluid sampling will be performed
before grafting and at each weekly review.
Skin punch biopsies (4 mm) will be taken from two
locations, at the centre of the wound and at the wound
edge, after administering adequate local anaesthesia (2 %
lidocaine). This procedure will be done prior to grafting
and repeated at day 7 post-grafting. The specimens are
then placed in a sterile vial containing 4 % paraformal-
dehyde and transferred to the laboratory.
Laboratory studies methodology summary
The methodology is summarized as follows:
1. The wound exudate samples will be used to
determine the type and concentration of growth
factors, pre-grafting and post-grafting, using an
enzyme-linked immunosorbent assay (ELISA) [6].
2. The skin biopsies will be used to compare the
expression pattern of keratinocyte proliferative
markers and Connexin protein (gap junctional
proteins) before and after grafting at the wound
edge and the centre of the wound. Tissues will be
cryosectioned and stained with haematoxylin and
eosin (H&E) and analysed for
immunohistochemistry [7].
Study outcome
The co-primary endpoints are the proportion of wounds
with complete healing at 6 weeks post-grafting and the
time for donor-site healing. Complete wound healing is
defined as 100 % re-epithelialisation. The assessment of
wound healing will be done via wound measurement at
each review. The three-dimensional photographs of the
wounds and the donor sites will be taken at each weekly
visit using a LifeViz 3D camera (from Quanticare or
similar) to obtain high-quality, accurate, and standar-
dised images for digital measurement of the wound sur-
face area [8]. These images will be stored in the patient’s
digital photo diary. An independent blinded analysis of
the photo diary will be carried out by two plastic
surgeons. Inter-rater and intra-rater reliability will also
be assessed. The wounds and the donor sites will be
assessed using the PUSH tool, a standardised wound as-
sessment tool, at each visit [9]. The PUSH scores for the
wounds and the donor sites will be statistically analysed.
The secondary endpoints include the mean time for
complete wound healing; pain score as reported by the
patients using a numerical rating scale (scale of 0–10);
patient satisfaction measured using a validated patient
skin graft satisfaction questionnaire [10]; healthcare util-
isation; and cost analysis measured by the consumables
used, the frequency of visits, and the incidence of ad-
verse events. The incidence of serious adverse events
(SAEs) include mortality of any cause within the 3-
month duration from the time of initial therapy, the in-
cidence of device-related adverse events (DAEs), and the
incidence of wound-related adverse events (WAEs) oc-
curring within the study duration. The patient skin graft
satisfaction questionnaire will be completed by the
participants at the 6-week and 3-month visit.
Furthermore, we will determine the wound-healing
mechanism of EG compared to SSG by analysing the
type and concentration of growth factors expressed by
the grafts, as well as the expression of Connexin proteins
(gap junctional protein) and keratinocyte proliferative
markers at the wound edge and the centre of the wound
before and after grafting.
Participant timeline
The study was opened to recruitment in October 2015
and is anticipated to close in September 2017. Each
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patient will be followed up weekly for 6 weeks or until
the wound heals. The final review will be at the third
month from the initiation of the treatment. If the pri-
mary intervention had failed at week 6 ± 2, re-grafting
and repeat of biopsy as per protocol will be considered
after discussing with patient. Failed intervention is de-
fined as increasing wound size or failure of 50 % reduc-
tion in wound size at week 6 ± 2. Figure 1 summarises
the patient’s journey throughout the trial.
Sample size
Our pilot study revealed that both techniques offer the
same healing rate at 6-weeks post-grafting; however, the
donor site morbidity is present in 40 % of the patients
with split-thickness skin graft while only 5 % is seen in pa-
tients with the epidermal graft. Donor site morbidity in-
cludes discolouration, scarring, pain, and risk of infection.
Given a significance level of 0.05 for 80 % power, a sam-
ple size of 19 patients per group is yielded. In
consideration of a potential dropout rate of 15 %, adjust-
ments have been made to the sample size, with an in-
crease to 22 patients per treatment arm. A total of 44
patients will be recruited into the study. The timeline for
recruitment is 24 months.
Randomisation, allocation concealment, and blinding
Once consented, patients will be randomly assigned to
one of the treatment groups. A random allocation se-
quence will be computer generated using SPSS version
22 (IBM, Armonk, NY, USA). The allocation sequence
will be sealed in identical opaque envelopes and given to
the enrolling researcher upon receipt of patient consent.
The surgical team, clinical staff, and patient will not be
blinded to the intervention status.
Data collection and management
All data collected will be recorded on paper forms and
in a digital clinical research folder (CRF). Data will be
Wound bed preparation
Patient screened & a patient information leaflet given
Patient consented & enrolled
Wound
exudate
and biopsy
samples
sent to the
laboratory
Patient followed up weekly for 6 weeks in the clinic or until the wound  heals
Patient reviewed on day 7 ± 2 and undergoes wound exudate
sampling and 4-mm punch biopsies
Patient undergoes wound exudate sampling and 4-mm punch
biopsies followed by treatment
Split thickness
skin graft (n=22)
Epidermal graft
(n=22)
Randomisation
(n=44)
Final review at 3 months from the initiation of treatment
Patient referred by a consultant plastic surge on for skin grafting
Fig. 1 Flow chart illustrating patient’s journey throughout the study
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collected by the surgical team and trial personnel. A
research fellow will ensure the accuracy of the data col-
lection by performing sample assessments at regular
intervals. Any adverse events will be recorded and re-
ported to the primary investigators and the institutional
ethics committee.
Wounds will be assessed and recorded in a wound
assessment form at each visit. Details on patient’s co-
morbidities, wound duration and type, and previous
wound bed-preparation methods will be recorded. The
three-dimensional photographs will be used to measure
the wound surface area digitally. The number and cost
of outpatient visits will be recorded, and the type and
cost of the dressings used will be documented.
Data storage
The multidisciplinary healthcare professionals at the out-
patient clinic will have access to participants’ personal
data to enable them to provide patient care. The data ex-
tracted for the purposes of this study will be anon-
ymised. All personal data extracted will be stored in the
trust computers, which can only be accessed by research
investigators and are password protected with restricted
access to unauthorised individuals. The computers are
encrypted and kept in a secure building with swipe card
access. Access to the computers will be via a secure
login. All handling, processing, and storage of personal
identifiable data and study data will be in accordance
with the Data Protection Act 1998 and the NHS Code of
Confidentiality.
We will store research data generated by the study for
5 years at UCL. The chief investigator will have long-
term access to research data after the study has ended.
Statistical analysis
All analysis will be conducted according to the intention-
to-treat principle with the use of SPSS version 22 (IBM,
Armonk, NY, USA). Patients are evaluated for analysis if
they received a study treatment. If the clinical course can-
not be fully evaluated, the last point of visit is considered
as the last data analysed. Baseline characteristics of the
two groups will be recorded. The continuous variables
will be compared using Student’s t-test. The categorical
variables will be compared using Pearson’s chi-square or
Fisher’s exact test depending on the number of events.
The proportion of wounds healed with each treatment
will be compared using a chi-square test or Fisher’s exact
tests, depending on the number of events. Mean time to
wound healing will be determined on the basis of the
number of days until complete re-epithelialisation, using
Kaplan-Meier analysis of cumulative wound healing,
followed by a log rank test.
Secondary outcomes will be compared between groups
using a chi-square test for categorical variables. Non-
normally distributed continuous variables will be compared
using a Mann-Whitney U test. A p value of less than
0.05 will be considered significant, and all tests will
be two-sided.
Discussion
Wound care presents a significant financial and resource
burden to the healthcare system, with about £5.0 billion
spent annually in caring for patients with wounds in the
United Kingdom alone. This signifies a need to further
optimise the current wound coverage strategies [11, 12].
EG for wound healing is not a new concept, and several
case reports have reported a good wound healing out-
come; however, it is not known if the healing rate is
comparable to SSG, a mainstay of treatment for wounds
that cannot be closed primarily [2, 5, 13].
EPIGRAAFT is designed as a randomised, controlled,
parallel-group, multicentre study to investigate the effi-
cacy of EG against SSG. Our hypothesis is that EG has
the same wound healing outcome with SSG but with
lower donor site morbidity. This trial design is pragmatic
with scientific evaluation on the wound-healing mechan-
ism by EG and SSG to promote further understanding
and compare the mechanism of healing at the cellular
level. It is postulated that EG stimulates wound healing
by acting like a bioengineered skin by expressing growth
factors, thereby encouraging the wound bed to regener-
ate, and initiates keratinocyte migration from the edges
of the wound [2]. In vitro studies showed that the mi-
grating keratinocytes from the grafts synthesise several
growth factors, namely the vascular endothelial growth
factor, hepatocyte growth factor, granulocyte colony-
stimulating factor, platelet-derived growth factor, and
transforming growth factor α [14, 15]. The migrating
keratinocytes also deposit a variety of extracellular
matrix components, such as laminin, fibronectin, and
type IV collagen [16]. The wound exudate analysis in this
trial will demonstrate the expression pattern of the
growth factors expressed by the grafts in vivo. The effect
of the growth factors on the wound bed and the edges
of the wound will be further confirmed by the punch bi-
opsies. The punch biopsy taken from the centre of the
wound will be used to identify the expression pattern of
the keratinocyte proliferative markers before and after
treatment, which could suggest the activation of the
wound bed with treatment. The skin biopsy from the
wound edge will be used to study the migratory activity
of the keratinocytes by determining the expression pat-
tern of the Connexin proteins. The Connexin proteins
are gap junctional proteins which are channel-forming
proteins enabling adjacent cells to communicate and
play a vital role in coordinating cell proliferation and
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migration [17]. It is known that the downregulation of
Connexin protein at the edges of the wound correlates
with increased keratinocytes migratory activity, resulting
in accelerated wound healing [17]. As the EG is postu-
lated to stimulate the keratinocytes at the wound edges
to proliferate and migrate onto the wound bed, down-
regulation of the Connexin protein is expected at the
wound edges. This, in turn, indicates that the keratino-
cytes have increased migratory properties. This will
also be correlated with the proliferation markers of
keratinocytes.
This study is expected to define the efficacy of EG and
further understand the mechanism of wound healing by
EG compared to SSG. These results can be used to
inform the current best practise for wound care.
Trial status
At the time of manuscript submission, the trial was
actively enrolling participants.
Dissemination policy
The results of the study will be reported and dissemi-
nated in peer-reviewed scientific journals, conference
presentations, and website/online publications, as well
as in internal reports. Reporting will be based on
CONSORT guideline for reporting randomised trials.
All publications will be forwarded to participants.
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